Table 2– Long-term (24 month) treatment outcomes after treatment with delamanid in combination with an optimised background treatment regimen: MDR- and XDR-TB patients

Treatment outcome	Long-term treatment^#	Short-term treatment^¶	All patients⁺
Favourable	143 (74.5; 67.7–80.5)^§	126 (55.0; 48.3–61.6)^§	269 (63.9; 59.1–68.5)
Cured	110 (57.3; 50.0–64.4)	111 (48.5; 41.8–55.1)	221 (52.5; 47.6–57.4)
Completed	33 (17.2; 12.1–23.3)^§	15 (6.6; 3.7–10.6)^§	48 (11.4; 8.5–14.8)
Unfavourable	49 (25.5; 19.5–32.3)^§	103 (45.0; 38.4–51.7)^§	152 (36.1; 31.5–40.9)
Died	2 (1.0; 0.1–3.7)^§	19 (8.3; 5.1–12.7)^§	21 (5.0; 3.1–7.5)
Failed	32 (16.7; 11.7–22.7)	26 (11.4; 7.6–16.2)	58 (13.8; 10.6–17.4)
Defaulted	15 (7.8; 4.4–12.6)^§	58 (25.3; 19.8–31.5)^§	73 (17.3; 13.8–21.3)

Data are presented as n (%; 95% CI). MDR: multidrug-resistant; TB: tuberculosis; XDR: extensively drug-resistant. ^#: 192 patients received delamanid (100 mg and/or 200 mg twice a day) for at least 6 months; ^¶: 229 patients received delamanid (100 mg or 200 mg twice a day) or placebo for 2 months; ⁺: n=421; ^§: differences between the long-term and the short-term treatment groups for the corresponding treatment outcome were statistically significant (p<0.001), all other differences did not reach statistical significance (p≥0.05).